MedTrace Logo

Safety Study of Single Administration Post-Exposure Prophylaxis Treatment for Ebola Virus

NCT01353027 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 30

Last updated 2012-03-28

No results posted yet for this study

Summary

The purpose of this study is to characterize the safety and pharmacology of single administrations of AVI-6002, a post-exposure prophylaxis candidate treatment for Ebolavirus.

Conditions

  • Ebola Hemorrhagic Fever

Interventions

DRUG

Placebo

Normal saline

DRUG

AVI-6002

Single intravenous administration

Sponsors & Collaborators

  • United States Department of Defense

    collaborator FED

  • Sarepta Therapeutics, Inc.

    lead INDUSTRY

Principal Investigators

  • William B Smith, MD · New Orleans Center for Clinical Research-Knoxville

  • Alison Heald, MD · Sarepta Therapeutics, Inc.

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
50 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2010-05-31
Primary Completion
2011-11-30
Completion
2011-11-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01353027 on ClinicalTrials.gov